CAMP Stock — CAMP4 Therapeutics Corporation: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.06

Market cap

$254.8M

Cash

$124.5M

Enterprise value

$130.3M

Balance sheet

Cash	$124.5M
Debt	$0.0M
Net cash	$124.5M
Enterprise value	$130.3M
Basic shares	62.8M shares
Fully diluted shares	76.5M shares
Fully diluted market cap	$310.7M
Cash per share	$1.98
Quarterly burn	$12.7M
Cash runway	6.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

62.8M

Pre-funded warrants

6.0M

Options

6.8M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.9M

FDSO

76.5M

Cap table as of 2026-08-12.

Price history

Loading CAMP daily closes…

Loading price history…

Next catalyst

CMP-CPS-001 · Jan 12 - Feb 23 in 14 mo · Phase 1 · Healthy Volunteers; OTC Deficiency

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 14 mo	CMP-CPS-001	Phase 1	Healthy Volunteers; OTC Deficiency	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CMP-002

Phase 2 · Active Modality: ASO

Target SYNGAP1

Indications

SYNGAP1-related disorder (Phase 2)

Status note Lead product candidate; intrathecally delivered ASO. Cleared to initiate Phase 1/2 clinical trial by Australia's TGA (July 2026) and Argentina's ANMAT; U.S. trial subject to FDA IND acceptance. Company also holds RAP Platform collaborations with Fulcrum, BioMarin, and GSK, none tied to CMP-002 in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CMP-CPS-001
Lead indication	Healthy Volunteers
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06247670	Phase 1	Active, not recruiting	Sponsor	CAMP	—	Healthy Volunteers; OTC Deficiency	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for CAMP4 Therapeutics Corporation on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Vivo Capital	4,246,568	no change	1.69%	2026-08-14
Stonepine Capital	1,389,622	no change	4.62%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CAMP — CAMP4 Therapeutics Corporation ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CAMP — CAMP4 Therapeutics Corporation